p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor
- PMID: 2566907
- PMCID: PMC362707
- DOI: 10.1128/mcb.9.3.1165-1172.1989
p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor
Abstract
The HER2/c-erbB-2 gene encodes the epidermal growth factor receptorlike human homolog of the rat neu oncogene. Amplification of this gene in primary breast carcinomas has been show to correlate with poor clinical prognosis for certain cancer patients. We show here that a monoclonal antibody directed against the extracellular domain of p185HER2 specifically inhibits the growth of breast tumor-derived cell lines overexpressing the HER2/c-erbB-2 gene product and prevents HER2/c-erbB-2-transformed NIH 3T3 cells from forming colonies in soft agar. Furthermore, resistance to the cytotoxic effect of tumor necrosis factor alpha, which has been shown to be a consequence of HER2/c-erbB-2 overexpression, is significantly reduced in the presence of this antibody.
Similar articles
-
Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies.Cancer Immunol Immunother. 1993 Sep;37(4):255-63. doi: 10.1007/BF01518520. Cancer Immunol Immunother. 1993. PMID: 8102322 Free PMC article.
-
Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic.J Clin Immunol. 1991 May;11(3):117-27. doi: 10.1007/BF00918679. J Clin Immunol. 1991. PMID: 1679763 Review.
-
Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu.Breast Cancer Res Treat. 1992;24(2):85-95. doi: 10.1007/BF01961241. Breast Cancer Res Treat. 1992. PMID: 8095168
-
The extracellular domain of HER2/neu is a potential immunogen for active specific immunotherapy of breast cancer.J Biol Response Mod. 1990 Oct;9(5):449-55. J Biol Response Mod. 1990. PMID: 1979347
-
Targeting HER2: recent developments and future directions for breast cancer patients.Semin Oncol. 2001 Dec;28(6 Suppl 18):21-9. doi: 10.1053/sonc.2001.29724. Semin Oncol. 2001. PMID: 11774202 Review.
Cited by
-
Fully automated fluorescent in situ hybridization (FISH) staining and digital analysis of HER2 in breast cancer: a validation study.PLoS One. 2015 Apr 6;10(4):e0123201. doi: 10.1371/journal.pone.0123201. eCollection 2015. PLoS One. 2015. PMID: 25844540 Free PMC article.
-
Circulating and disseminated tumor cells: diagnostic tools and therapeutic targets in motion.Oncotarget. 2017 Jan 3;8(1):1884-1912. doi: 10.18632/oncotarget.12242. Oncotarget. 2017. PMID: 27683128 Free PMC article. Review.
-
Oncoprotein stability after tumour resection.Br J Cancer. 1990 Apr;61(4):538-42. doi: 10.1038/bjc.1990.121. Br J Cancer. 1990. PMID: 2139576 Free PMC article.
-
Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth.Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8691-5. doi: 10.1073/pnas.88.19.8691. Proc Natl Acad Sci U S A. 1991. PMID: 1717984 Free PMC article.
-
Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer.Breast Cancer Res. 2003;5(2):96-100. doi: 10.1186/bcr574. Epub 2003 Feb 3. Breast Cancer Res. 2003. PMID: 12631388 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous